FDA: Evusheld may not prevent COVID-19 caused by certain variantsÂ
The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the Food and Drug Administration this week. For details, see the .
FDA last year authorized the combination monoclonal antibody therapy for emergency use to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components. FDA continues to recommend Evusheld to prevent COVID-19 as it still offers protection against many circulating variants, but encourages patients to be prepared to test and seek immediate treatment if they experience COVID-19 symptoms. The agency also continues to recommend that people who can get vaccinated and boosted to prevent COVID-19.